Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 5;17(3):e80103.
doi: 10.7759/cureus.80103. eCollection 2025 Mar.

C-peptide Trajectory Following Pancreas Transplantation

Jordan A Williamson  1 , Kayla J Dobies  1 , Abraham M Velazquez  1 , Oliver G Ralph  1 , Oyedolamu Olaitan  1
Affiliations

C-peptide Trajectory Following Pancreas Transplantation

Jordan A Williamson et al. Cureus. .

Abstract

Background: Pancreas transplantation is the most reliable management of insulin-dependent diabetes mellitus, offering sustained glycemic control with a reduction in diabetes-related complications. Despite recent advancements, recipient selection criteria are not standardized. Historically, pre-transplant C-peptide level was an important indicator of post-transplant success, yet conflicting data exist regarding their correlation. This study explores post-transplant C-peptide trends in recipients with varying pre-transplant C-peptide levels, aiming to elucidate its impact on patient and graft survival.

Methods: A retrospective review of 78 pancreas transplant recipients (simultaneous pancreas and kidney, pancreas after kidney, and pancreas transplant alone) from September 2012 to August 2022 was conducted. Patients were categorized based on pre-transplant C-peptide levels (>4.0 ng/mL elevated vs. ≤4.0 ng/mL low/normal). C-peptide levels, HbA1c, and estimated glomerular filtration rate (eGFR) were monitored at specified intervals post-transplant.

Results: The two cohorts exhibited disparate post-transplant C-peptide trends; elevated (pre-transplant: mean = 8.43 ng/mL, range = 4-28.26 ng/mL; post-transplant: mean = 3.57 ng/mL, range = 0.84-8.53 ng/mL) and low/normal (pre-transplant: mean = 1.07 ng/mL, range = 0-3.92 ng/mL; post-transplant: mean = 2.81 ng/mL, range = 0.9-6.73 ng/mL). Despite achieving normoglycemic control (HbA1c 5.26% and 5.19%, respectively), the decline in C-peptide levels in the elevated pre-transplant group contradicted the anticipated outcomes.

Conclusion: This study highlights the intricate dynamics of post-transplant C-peptide, revealing unexpected patterns in recipients with elevated pre-transplant C-peptide levels. The study's findings question the predictive value of pre-transplant C-peptide levels and underscore the importance of further research to unravel its metabolism post-transplant.

Keywords: c-peptide; glomerular filtration rate; pancreas transplantation; patient outcome assessment; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Kaplan-Meier curve comparing baseline C-peptide levels and pancreas graft survival up to five years post-transplant
See this image and copyright information in PMC

References

    1. Generation of insulin-secreting organoids: a step toward engineering and transplanting the bioartificial pancreas. Wassmer CH, Lebreton F, Bellofatto K, Bosco D, Berney T, Berishvili E. Transpl Int. 2020;33:1577–1588. - PMC - PubMed
    1. Pancreas transplantation: indications, techniques, and outcomes. Samoylova ML, Borle D, Ravindra KV. Surg Clin North Am. 2019;99:87–101. - PubMed
    1. Transplant strategies for type 1 diabetes: whole pancreas, islet and porcine beta cell therapies. Bellin MD, Dunn TB. Diabetologia. 2020;63:2049–2056. - PubMed
    1. OPTN/SRTR 2019 annual data report: pancreas. Kandaswamy R, Stock PG, Miller J, et al. Am J Transplant. 2021;21 Suppl 2:138–207. - PubMed
    1. C-peptide levels do not correlate with pancreas allograft failure: multicenter retrospective analysis and discussion of the new OPT definition of pancreas allograft failure. Niederhaus SV, Carrico RJ, Prentice MA, et al. Am J Transplant. 2019;19:1178–1186. - PubMed

LinkOut - more resources